Hospitals Struggle To Supply COVID-19 Teams With The Medicines They Need
Executive Summary
Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.
You may also be interested in...
COVID-19 Shows US FDA Why It Needs To Know Supply Chain’s Current And Surge Capacities
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.
As Other US Agencies Respond To The Pandemic, FEMA Fine-Tunes Plan Of Action
Industry wonders how emergency agency's COVID-19 public-private partnerships will fit in with the others.
USP Building Risk Model To Assess Supply Chain Vulnerabilities And Anticipate Drug Shortages
The USP is developing a risk model to assess whether pharmaceutical supply chains are strong or weak based on demand for reference standards.